Header Logo

Connection

KIM-ANH DO to High-Throughput Nucleotide Sequencing

Back to Details
This is a "connection" page, showing publications KIM-ANH DO has written about High-Throughput Nucleotide Sequencing.
KIM-ANH DO
Connection Strength
0.023
High-Throughput Nucleotide Sequencing
  1. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.